VF
BNTC icon

Virtu Financial’s Benitec Biopharma BNTC Stock Holding History

Virtu Financial’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,110
Closed -$13K – 1337
2023
Q2 		$13K Sell
3,110
-4,038
-56% -$15.4K ﹤0.01% 1322
2023
Q1 		$26K Buy
7,148
+2,391
+50% +$9.75K ﹤0.01% 1194
2022
Q4 		$14K Buy
+4,757
New +$16.1K ﹤0.01% 1330
2022
Q3 		– Sell
-2,788
Closed -$55K – 1747
2022
Q2 		$55K Buy
+2,788
New +$64.8K ﹤0.01% 1097
2022
Q1 		– Sell
-615
Closed -$27K – 1518
2021
Q4 		$27K Sell
615
-733
-54% -$40.9K ﹤0.01% 1470
2021
Q3 		$82K Buy
+1,348
New +$88.5K 0.01% 1191
2021
Q2 		– Sell
-1,325
Closed -$116K – 1533
2021
Q1 		$116K Buy
1,325
+201
+18% +$13.7K 0.01% 1275
2020
Q4 		$57K Buy
+1,124
New +$55.9K 0.01% 1206
2019
Q4 		– Sell
-44
Closed -$8K – 1455
2019
Q3 		$8K Buy
+44
New +$8.09K ﹤0.01% 1359

Other funds holding BNTC

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Virtu Financial's BNTC Position: Q3 2023 in Review

Virtu Financial sold out of Benitec Biopharma (BNTC) in Q3 2023, closing a stake of 3,110 shares — an estimated $13K sold.

Virtu Financial first reported a position in BNTC in Q3 2019 and held it in 9 quarters. The position peaked at $116K in Q1 2021. 12 funds tracked by Wall St. Rank hold BNTC as of Q3 2023.

  • Virtu Financial reported no remaining Benitec Biopharma position as of Q3 2023 after selling out during the quarter.
  • Virtu Financial sold 3,110 Benitec Biopharma shares in Q3 2023, an estimated $13K.
  • Virtu Financial first reported a position in Benitec Biopharma in Q3 2019 and held it in 9 quarters.
  • Virtu Financial's Benitec Biopharma position peaked at $116K in Q1 2021.
  • 12 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2023.

Based on Virtu Financial's 13F filing for Q3 2023, filed 15 Nov 2023.